Nilotinib Stada (Nilotinib)

Nilotinib binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that promotes leukemic cell proliferation and survival, leading to apoptosis of malignant cells while largely sparing normal tissues.

The prescribed dose of Nilotinib Stada is determined by the treating physician based on the patient’s disease phase, prior therapies, and individual health status. Dosing instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for nilotinib in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity than first‑generation agents such as imatinib. It is often chosen for patients who have resistance or intolerance to earlier therapies, though the choice depends on individual clinical factors and physician judgment.

Store Nilotinib Stada at room temperature, below 25 °C, in the original blister or bottle. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Nilotinib Stada is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatic injury, pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of cardiac, liver and pancreatic function is essential.

Nilotinib Stada is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in those with a history of prolonged QT interval or uncontrolled cardiac arrhythmias. Caution is also advised for patients taking strong CYP3A4 inhibitors or inducers.